文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles.

作者信息

Zhou Yan, Liu Min, Huang Xing, Liu Zhen, Sun Yun, Wang Minjie, Huang Tao, Wang Xianke, Chen Long, Jiang Xiaobing

机构信息

Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.

出版信息

Front Oncol. 2024 Jan 12;13:1307924. doi: 10.3389/fonc.2023.1307924. eCollection 2023.


DOI:10.3389/fonc.2023.1307924
PMID:38293697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10825959/
Abstract

PURPOSE: This study aims to depict the scientific advancements in immunotherapy for glioma by analyzing the top 100 most frequently cited articles over the past 20 years. METHODS: The top 100 most influential papers in immunotherapy for glioma were identified from the Web of Science Core Collection. Citations, countries/regions, institutions, journals, authorships, keywords, and references were extracted and analyzed by CiteSpace, VOSviewer, R software, and an online bibliometric platform. RESULTS: The United States possessed a robust global presence, leading in terms of publications and maintaining strong collaborative ties with numerous countries. The institution that made the greatest contributions was Duke University, with 16 papers. Heimberger AB, Sampson JH, and Reardon DA secured the top three positions with 15, 12, and 11 papers, respectively. "Macrophage ontogeny," "microglia," "polarization," "mass cytometry," "tumor mutation burden," "sensitivity," "msh6," "pd-1 blockade," and "dna repair" were the recent hot keywords. "Microglia" and "polarization" as the emerging research directions should be given more consideration. CONCLUSIONS: This is the first bibliometric analysis to identify the top 100 papers on immunotherapy for glioma. "Microglia" and "polarization" will be hot spots for future research. The clinical efficacy of glioma immunotherapy is not yet satisfactory, and there is an urgent need to search for more tumor specific antigens and targets that can assist in early diagnosis, precise treatment, prognosis, and recurrence prediction of glioma.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/7187a7855fda/fonc-13-1307924-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/7dc6bd133a08/fonc-13-1307924-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/8f87a69835d8/fonc-13-1307924-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/56159eaf2a29/fonc-13-1307924-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/79195b0c9ae8/fonc-13-1307924-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/267d832717be/fonc-13-1307924-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/a876bb7be950/fonc-13-1307924-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/7187a7855fda/fonc-13-1307924-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/7dc6bd133a08/fonc-13-1307924-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/8f87a69835d8/fonc-13-1307924-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/56159eaf2a29/fonc-13-1307924-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/79195b0c9ae8/fonc-13-1307924-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/267d832717be/fonc-13-1307924-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/a876bb7be950/fonc-13-1307924-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7051/10825959/7187a7855fda/fonc-13-1307924-g007.jpg

相似文献

[1]
Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles.

Front Oncol. 2024-1-12

[2]
Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.

Front Oncol. 2023-8-21

[3]
Bibliometric study of immunotherapy for hepatocellular carcinoma.

Front Immunol. 2023

[4]
The Top 100 Cited Articles Focusing on Acute Lung Injury and ARDS: Bibliometric and Visualization Analyses.

Respir Care. 2024-7-24

[5]
Current perspectives and trends of CD39-CD73-eAdo/A2aR research in tumor microenvironment: a bibliometric analysis.

Front Immunol. 2024

[6]
Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.

Front Endocrinol (Lausanne). 2023

[7]
Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis.

Front Oncol. 2024-8-7

[8]
Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis.

Front Pharmacol. 2024-1-8

[9]
Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021).

Front Immunol. 2022

[10]
Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.

Front Oncol. 2022-11-17

引用本文的文献

[1]
AO Spine Knowledge Forums Promote Collaboration and Elevate the Impact of Research: A Bibliometric Analysis.

Global Spine J. 2025-6-13

[2]
Research hotspots and development trends of spondylitis in the past 30 years: a bibliometric analysis.

Front Microbiol. 2025-2-19

[3]
Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis.

Hum Vaccin Immunother. 2025-12

[4]
Deep brain stimulation for Parkinson's disease: bibliometric analysis of the top 100 cited literature.

Front Aging Neurosci. 2024-10-16

[5]
The top 100 most cited articles on mucopolysaccharidoses: a bibliometric analysis.

Front Genet. 2024-4-12

本文引用的文献

[1]
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.

JAMA Netw Open. 2023-1-3

[2]
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.

Mol Cancer. 2023-1-9

[3]
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.

J Exp Clin Cancer Res. 2022-12-14

[4]
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

JAMA Oncol. 2023-1-1

[5]
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

J Hematol Oncol. 2022-10-8

[6]
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.

Breast. 2022-12

[7]
The current state of the art and future trends in RAS-targeted cancer therapies.

Nat Rev Clin Oncol. 2022-10

[8]
The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials.

Crit Rev Oncol Hematol. 2022-5

[9]
Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy.

Natl Sci Rev. 2021-9-21

[10]
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.

Nature. 2022-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索